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Abstract
Objective—Although a useful marker of heart failure in adults, the utility of brain natriuretic
peptide concentration (BNP) for children after the Fontan procedure is not well studied.
Design—BNP was measured in 510 patients aged 6–18 years in the Pediatric Heart Network
Fontan cross-sectional study at a median of 8.2 years after Fontan. Patients underwent
echocardiography, exercise testing, magnetic resonance imaging (MRI) and functional health
status questionnaires. Associations of BNP with baseline patient characteristics, medical history
and cross-sectional assessment were examined with multivariable linear regression analyses.
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Results—The distribution of BNP was highly skewed, median 13.0 pg/mL (inter-quartile range:
7.1, 25.9), and was normalized with logarithmic transformation (logBNP). Among medical history
variables, logBNP was greater in females (p=0.02) and older patients (p<0.001). Presence of preFontan systolic ventricular dysfunction, greater number of post-Fontan complications, and
thrombosis after Fontan were independently associated with higher logBNP (R2=0.16). Ageadjusted logBNP was significantly related to Fontan connection type, (lower with extracardiac
conduits, higher with atriopulmonary connection; p<0.001). Lower physical functioning health
status (R2=0.05), lower chronotropic index during exercise (R2=0.17), indices of diastolic
dysfunction measured by echocardiography (R2=0.15), and higher total ventricular mass on MRI
(R2=0.33) were related to higher logBNP.
Conclusions—Despite a markedly abnormal circulation, BNP was variable but within a normal
range in the majority of Fontan patients in this large outpatient cohort. Higher BNP was associated
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with several markers of suboptimal outcome, although associations were weak. The routine use of
BNP as an outpatient surveillance tool in asymptomatic Fontan patients is not warranted.
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INTRODUCTION
Brain natriuretic peptide is a naturally occurring hormone produced by cardiac ventricular
and, to a lesser extent, atrial myocytes in physiologic situations associated with ventricular
or atrial wall stress. Brain natriuretic peptide concentration (BNP) has been widely used as a
diagnostic tool to differentiate cardiac from respiratory illnesses in adults.1, 2 Studies of
BNP in pediatric patients with heart disease are limited and are frequently not adjusted for
factors such as age and gender that confound measurements. In small studies involving
children with heterogeneous congenital heart diagnoses, elevated BNP correlated with
ventricular dysfunction.3 Patients with functionally univentricular hearts had higher BNP
compared to those with a biventricular circulation.4 There is limited published information
about BNP in Fontan patients and the potential diagnostic and prognostic value of BNP in
this population is currently unknown.
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The Pediatric Heart Network (PHN) recently completed a multi-institutional cross-sectional
study of outpatient Fontan subjects aged 6 to 18 years.5, 6 The purpose of the present report
is to describe the profile of BNP in children and adolescents after the Fontan procedure and
its relationship to subject characteristics and medical history. Furthermore, we sought to
identify laboratory factors that are associated with BNP using cross-sectional tests of
functional health status, exercise performance, echocardiography and cardiac magnetic
resonance imaging (MRI).

METHODS
Study Subjects
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The seven centers comprising the PHN performed a multicenter, prospective, cross-sectional
assessment of children who had undergone a Fontan procedure.6 The techniques used to
collect medical history data and to perform standardized echocardiography, cardiac MRI,
and exercise testing have been previously described. 5, 6 Potential study subjects were
identified from medical record review, and deemed eligible if they were age 6 to 18 years at
the time of enrollment; had undergone Fontan procedure at least 6 months before initial
study testing; and agreed to have an echocardiogram and blood testing and to complete a
parent report functional health status questionnaire within 3 months of enrollment at one of
the study centers. Exclusion criteria included the presence of a non-cardiac medical or
psychiatric disorder that would prevent successful completion or invalidate the results of
study testing. Subjects (n=546) were evaluated at a mean age of nearly 12 years old, and at a
mean interval of 8.6 years after Fontan completion.5 The protocol was approved by each
center's institutional review board. Written informed consent and assent were obtained. The
present analysis is limited to the 510 subjects with BNP measurements.
Measurements
Resting BNP in plasma was centrally measured with the Shinogi BNP-32 Human Assay
(Mayo Clinical Trial Services, Rochester, MN).6 The samples were drawn from a
venipuncture after patients had been in a sitting or supine position in a quiet room for 30
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minutes. The lower detection limit was 4 pg/mL; this was used for 55 subjects whose values
were denoted as below the detectable limit.
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Among the 510 subjects with BNP measured, functional health status was assessed in 504
using the validated Parent Report Form of the Child Health Questionnaire (CHQ).7 In
addition to scores for individual domains, summary scores were derived for Physical and
Psychosocial Functioning. The Parent Report Form of the CHQ also required parents to
identify from a list of associated health conditions those which were present in their child. A
previous analysis reported associations between Physical Functioning Summary Score and
patient and medical history characteristics.8 Exercise testing was performed in 390 of these
subjects. Analysis of the 6 exercise variables was limited to the 158 subjects able to achieve
maximal aerobic capacity (Peak Respiratory Exchange Ratio >1.1). Analysis of chronotropic
index (maximal achieved heart rate- resting heart rate) ÷ (predicted maximal heart rate
minus resting heart rate) was restricted to only the 135 non-paced subjects able to achieve
maximal exercise. Among the other exercise variables, the number of missing values was
small (<5 for each) and no imputation of missing values was performed. An echocardiogram
was performed for 503 patients with measured BNP. Subjects were excluded from analysis
of echocardiographic data if they had no available mass or volume data (n=114). Missing
echocardiographic variable values were imputed in multivariable regression analyses using
mean values from the subset with mass-volume data. An MRI was performed in 153
patients. Among the 7 MRI variables measured, very few values (<3 for each) were missing
and imputation was not performed.
Data Analysis
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Data are described as frequencies, medians with minimum and maximum values or 25th and
75th percentile values, and means with standard deviations. The distribution of BNP was
highly skewed towards lower values. (Figure 1). As a result, all analyses were performed
after logarithmic transformation (logBNP, natural logarithm), which resulted in a more
normal distribution. Variables explored for association with logBNP were initially analyzed
within associated groups (e.g., echocardiography, exercise testing, MRI) in univariable
models (Table 1) and then in multivariable models (Table 2). To determine the amount of
variation in logBNP explained by each group of variables, multivariable linear regression
analyses were performed with all variables from each group included in the model and the
R2 adjusted for the number of variables are reported (Table 2). To determine which variables
within each group were independently associated with logBNP, initial exploration was
performed using bootstrap procedures to determine reliability for model inclusion, and then
stepwise regression was performed with inclusion of gender and age at enrollment for
adjustment in final models. Non-linearity was addressed by a variable transformation, as
appropriate. Further adjustment for type of Fontan connection was performed by including
this variable in final regression models for echocardiography, exercise testing and MRI
variable groups. Given the large number of variables explored, only significant variables in
multivariable regression analyses are reported (Table 3). All analyses were performed using
SAS statistical software version 9 (SAS Institute, Inc, Cary, NC).

RESULTS
Study Subjects
BNP was measured in 510 of 546 subjects; 60% were male, 80% were white, 10% were
black, and 10% were of another race. Subjects were a median age of 11.4 years (interquartile range [IQR]: 9.0 – 14.6 yrs) at the time of enrollment, and underwent their Fontan
surgery at a median of 2.8 years (IQR: 2.1 – 4.0 yrs) of age. The 36 subjects without BNP
measurements in the Fontan cross sectional study were significantly younger than the 510

Congenit Heart Dis. Author manuscript; available in PMC 2012 July 1.

Atz et al.

Page 4

NIH-PA Author Manuscript

with a measurement (10.8 ± 3.4 years versus 11.9 ± 3.4 years, p=0.05), likely due to
reluctance to undergo venipuncture or technical difficulty. The mean BNP was 25 ± 48 pg/
mL, with a median of 13 pg/mL (range 4 to 652 pg/mL; IQR 7 to 26 pg/mL). The
distribution of BNP levels in the study sample is shown in Figure 1. Previous studies in
patients with congenital heart disease have suggested that BNP > 40 pg/mL may be a marker
of ventricular dysfunction 3 and may differentiate children with congestive heart failure
from those with non-cardiac causes of respiratory distress.9 A value of 100pg/mL has been
used as a marker for heart failure in adults. 2 Overall, 86% of subjects (n=438) had BNP <
40 pg/mL and 96% (n=489) had BNP <100pg/mL. Values below the detection level of 4pg/
mL occurred in 11% of subjects (n=55).
Association of Patient Variables to BNP
Table 2 shows the magnitude of the relationship of variable groups with logBNP. For all
variable groups, the proportion of variance in BNP explained by the variables (adjusted R2)
was small, being highest for echocardiography at 0.14 or 14%, followed by MRI at 9%, and
parent-completed CHQ associated health conditions at 8%.
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The results of the multivariable analyses for each variable group are shown in Table 3.
Higher logBNP was significantly and independently related to female gender and older age
at enrollment. Therefore, all other multivariable analyses were subsequently adjusted for
gender and age. The only pre-Fontan procedure characteristic significantly associated with
higher logBNP was the presence of systolic ventricular dysfunction by echocardiography.
Type of Fontan connection was the only significant Fontan procedure characteristic variable
independently associated with logBNP, (p< 0.01, Figure 2). Mean BNP (adjusted for age
and gender) among subjects with atriopulmonary connection was 8pg/mL higher than for
those with intracardiac lateral tunnel, which in turn was 11 units higher than BNP in those
with an extracardiac lateral tunnel, and BNP in those with an extracardiac lateral tunnel were
a mean of 4 pg/mL higher than those with an extracardiac conduit. Therefore, subsequent
multivariable analyses of laboratory testing were adjusted for this additional variable of
Fontan connection type. Post-Fontan characteristics independently associated with higher
logBNP included a greater number of complications and the presence of an episode of postFontan thrombosis. For the parent-completed CHQ, higher logBNP was associated with
lower Physical Functioning Summary and Physical Functioning domain scores, as well as
the presence of associated bone/joint/orthopedic and allergy/sinus problems.
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Multivariable analyses of laboratory testing results were performed with adjustments for
gender, age and type of Fontan connection (Table 3). From exercise testing, only lower
chronotropic index was associated with higher logBNP. Among echocardiographic
variables, indices of diastolic dysfunction were significantly related to higher logBNP.
Among MRI variables, only greater total ventricular mass indexed to body surface area was
associated with higher logBNP. To account for the non-linearity and improve model fit, a
dichotomous variable separating observations in the 95th percentile of the indexed
ventricular mass from the rest of the observations was used.
A number of variables were not associated with BNP. After adjustment for age at
enrollment, gender and type of Fontan connection, the following were not independently
associated with BNP: ventricular type (a dominant left, right or mixed ventricular
dominance), age at Fontan completion, and post-Fontan history of arrhythmia. Protein losing
enteropathy was documented in 19 subjects; median BNP was not different between those
and the remaining 491 subjects, 13 vs, 10 pg/mL, p=0.5. The presence or magnitude of
atrioventricular valve regurgitation assessed by echocardiogram was not associated with
BNP. Ejection fraction (EF) assessed as a continuous variable by echocardiography and
MRI was also not associated with BNP. However, when comparing subjects assessed by the
Congenit Heart Dis. Author manuscript; available in PMC 2012 July 1.
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echocardiography core lab to have a normal EF (z-score ≥−2, which corresponds to an EF ≥
53%) with those with abnormal EF (z-score < −2, which corresponds to an EF < 53%), we
found logBNP to be significantly lower in those with normal EF, p=0.01). When adjusted
for age and gender, those with normal EF continued to have a lower logBNP (p=0.02)

DISCUSSION
This is the largest study to date examining BNP in Fontan patients. A strength of the study is
its prospective design and centralized assay for BNP concentration. In addition, the analyses
were adjusted for known confounders such as age and gender. We found that BNP varied
considerably in this multicenter cohort of outpatient Fontan subjects, but was relatively low
in the majority of patients, especially compared to values used to define congestive heart
failure in adult patients. Higher BNP (or logBNP) was associated with older age, female
gender and atriopulmonary type Fontan connection, as well as selected medical history
variables. Higher BNP was weakly associated with diagnostic markers of suboptimal health
status and ventricular performance.
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Previous studies in patients with congenital heart disease have suggested that BNP > 40 pg/
mL may be a marker of ventricular dysfunction 3 and may differentiate children with
congestive heart failure from those with non-cardiac causes of respiratory distress.9, 10
Assigning specific cut-point values of BNP in pediatrics is uniquely problematic as normal
values are not widely agreed upon and, similar to what we report, vary with both gender and
age. 11, 12 In a group of 67 Fontan patents, BNP was reported as normal in 81%.13 The
data presented here suggest that the uniform and unisex cut-points for normal values for
BNP may be misleading and should not be used in this population.
BNP is elevated after initial palliative operations in single ventricle patients and falls in
response to subsequent volume unloading surgeries such as the cavopulmonary anastomosis
(Glenn) procedure.14 In a previous study involving single ventricle patients, plasma BNP
was elevated when systemic ventricular dysfunction was present but not elevated compared
to normal controls for patients with Glenn or Fontan physiology without ventricular
dysfunction. 15 Among our subjects, ejection fraction, a marker of systolic function, was
normal in 73% of subjects 5and those subjects had a lower logBNP when compared to those
with an abnormal ejection fraction.
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After controlling for age and gender, we found the type of Fontan connection was related to
BNP. Similarly, BNP was higher in a small study of adult Fontan patients with
atriopulmonary connections compared to those with total cavopulmonary connections. 16
Although the majority of BNP is secreted from ventricular myocytes, it is also secreted from
atrial myocytes, and therefore may be expected to be higher in anatomic situations of
increased atrial stretch such as with the atriopulmonary connection in comparison to
extracardiac connections.
We found a higher BNP to be weakly associated with lower (poorer) Physical Functioning
Summary Score and lower scores for the Physical Functioning domain. This is consistent
with findings in a small group of children after Fontan where higher NT-pro BNP was
associated with higher New York University Pediatric Heart Failure Index scores 17 and in
an older Fontan population where lower BNP differentiated NYHA classification 2 from
NYHA class 3 and 4. 16 The association of BNP to orthopedic/bone/joint problems and
allergy/sinus problems has not been previously reported and is not intuitively explained,
other than speculating that these findings may co-migrate with other indicators of poor
cardiac status.
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In the present study, a lower chronotropic index was independently associated with higher
BNP after consideration of age, gender and Fontan connection type. A lower chronotropic
index has been used as a marker for chronotropic incompetence, which has been shown to
be a predictor of sudden cardiac death in patients with heart failure.18 Although not
previously well studied in the Fontan population, chronotropic incompetence has been
associated with higher BNP in adults with congenital heart disease decades after their
surgical intervention. 19
The association of higher BNP with echocardiographic findings of diastolic dysfunction is
consistent with a previous study involving 35 asymptomatic Fontan patients. 20 The
association of BNP with increased ventricular mass noted in our patients undergoing MRI
has not been previously reported in this population, but BNP has been associated with
increased ventricular mass in adults with hypertrophic cardiomyopathy, 21 and in pediatric
patients with increased left ventricular mass as a result of aortic stenosis.22
After adjustment for age, gender and Fontan connection type neither the presence nor
magnitude of atrioventricular valve regurgitation was related to BNP. Again, this may
reflect well compensated hemodynamics in this relatively healthy cross-sectional study of
Fontan patients. Consistent with previous studies we found no difference in BNP related to
the dominant ventricular morphology (right, left or mixed). 16 17
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This study must be interpreted in light of some limitations. This was a cross-sectional study
of pediatric Fontan outpatients, and as such, the most symptomatic Fontan patients may not
have been included. This likely contributed to the rather narrow range of BNP values
measured in our study and may have impeded our efforts to find strong associations. In
addition, a cross-sectional study such as this cannot assess the predictive value of BNP for
outcomes such as death or progressive heart failure. Not all patients were able to complete
all tests, which might limit the ability to detect associations.
This study establishes a range of BNP concentrations in a large outpatient cohort of children
after the Fontan procedure. Despite a markedly abnormal circulation, BNP is within the
normal range for age in the majority of the subjects. Our data do not support the routine
measurement of BNP in the outpatient follow up of relatively healthy patients after a Fontan
procedure.
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Figure 1.
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Distribution of Brain natriuretic peptide (BNP) concentration excluding 4 patients with
values exceeding 200 pg/ml.
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Figure 2.
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Subgroup analysis of serum brain natriuretic peptide concentrations (BNP) by Fontan
connection type. Mean ± SE of raw BNP adjusted for gender and age at enrollment
APC=atriopulmonary connection, ECC=extracardiac conduit, ECLT=extracardiac lateral
tunnel, ICLT=intracardiac lateral tunnel.
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TABLE 1

Significant Variables in Univariable Testing for Association with Log Transformed BNP concentrations

NIH-PA Author Manuscript

Variable

n

PE (SE)

p Value

Age at enrollment

510

0.05 (0.01)

<0.01

Female gender

510

0.23 (0.09)

<0.01

White

406

0.23 (0.14)

Black

49

0.51 (0.19)

Other

54

reference

Body mass index Z score

509

0.03 (0.01)

<0.01

Years since Fontan

510

0.04 (0.01)

<0.01

History of stroke before Fontan

504

0.55 (0.22)

0.01

Systolic ventricular dysfunction before Fontan

468

0.46 (0.16)

<0.01

No Cavopulmonary staging procedure performed

510

0.33 (0.10)

<0.01

Higher ventricular end-diastolic pressure

486

0.03 (0.01)

0.04

Lower systemic oxygen saturation prior to Fontan

494

0.03 (0.01)

<0.01

Demographics

Race

0.02

Pre-Fontan Characteristics

NIH-PA Author Manuscript

Fontan Procedure Characteristics
Type of Fontan connection

<0.01

Atriopulmonary

69

−0.37 (0.30)

Intracardiac lateral tunnel

301

−0.76 (0.28)

Extracardiac lateral tunnel

63

−1.08 (0.30)

Extracardiac conduit

66

−1.22 (0.30)

Other

11

reference

Decreased systolic ventricular function at discharge

506

0.60 (0.23)

<0.01

Glycoside use at discharge

505

0.18 (0.09)

0.03

Total number of complications

510

0.12 (0.03)

<0.01

Post-Fontan thrombosis

510

0.60 (0.16)

<0.01

Post-Fontan arrhythmia

509

0.28 (0.10)

<0.01

Presence of other (non-cardiac) complications

510

0.21 (0.10)

0.03

Number of other (non-cardiac) complications

510

0.11 (0.04)

<0.01

Number of post-Fontan cardiac surgeries

510

0.10 (0.04)

0.02

Poorer Physical Functioning Summary score

483

0.01 (0.004)

<0.01

Poorer Physical functioning domain

503

0.01 (0.002)

<0.01

Poorer Bodily pain domain

498

0.01 (0.002)

0.01

Orthopedic problems

498

0.50 (0.13)

<0.01

Allergies / sinus problems

496

0.32 (0.11)

<0.01

Sleep disturbance

498

0.36 (0.14)

0.02

Post-Fontan Follow-Up Characteristics

NIH-PA Author Manuscript

Parent-Completed CHQ Scores

Parent-Completed CHQ Health Conditions
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NIH-PA Author Manuscript

Variable

n

PE (SE)

p Value

Asthma

491

0.27 (0.12)

0.03

135

1.54 (0.61)

0.01

Ventricular mass Z score

382

0.11 (0.02)

<0.01

Ventricular end-diastolic volume Z score

389

0.11 (0.02)

<0.01

Ventricular end-systolic volume Z score

389

0.08 (0.02)

<0.01

Ventricular stroke volume Z score

389

0.09 (0.03)

<0.01

Lower AW peak late diastolic velocity

258

1.52 (0.42)

<0.01

Duration of AW late diastolic inflow

258

0.01 (0.002)

<0.01

Ratio of early to late AW diastolic velocity

258

0.31 (0.10)

<0.01

Tei Index

347

0.68 (0.29)

0.02

Total ventricular mass indexed to body surface area

153

0.01 (0.003)

<0.01

Ratio of total ventricular mass to end-diastolic volume

153

0.80 (0.23)

<0.01

Lower ventricular ejection fraction

153

0.02 (0.01)

0.04

Cardiopulmonary Exercise Testing
Lower Chronotropic index
Echocardiography

Magnetic Resonance Imaging

NIH-PA Author Manuscript

PE, parameter estimate; SE, standard error; AW, atrioventricular valve; CHQ, Child Health Questionnaire; HLHS, hypoplastic left heart syndrome;
PHN, Pediatric Heart Network; SV, single ventricle
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TABLE 2

NIH-PA Author Manuscript

The Proportion of Variance (Model R2) in Log Transformed Brain Natriuretic Peptide Concentrations*
Explained in Multivariable Analysis by Groups of Variables
Variable Group

n

Number of
Variables

R2

Adjusted R2**

Demographics

510

8

0.08

0.06

Pre-Fontan characteristics

510

20

0.05

0.02

Fontan characteristics

510

31

0.15

0.10

Post-Fontan characteristics

510

14

0.05

0.03

Parent-completed CHQ summary scores

483

2

0.02

0.01

Parent-completed CHQ domain scores

504

15

0.08

0.05

Parent-completed CHQ health conditions

504

15

0.10

0.08

Cardiopulmonary exercise testing

131

6

0.06

0.02

Echocardiography†

389

16

0.17

0.14

Magnetic resonance imaging

151

7

0.11

0.09

*

analyzed after logarithmic transformation (with the natural base) to normalize the distribution

NIH-PA Author Manuscript

**

adjusted for the number of variables in the model

CHQ, Child Health Questionnaire
†

Missing echocardiographic variable values were imputed from the subset with mass-volume data
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TABLE 3

NIH-PA Author Manuscript

Final Multivariable Models for Higher Log Transformed Brain Natriuretic Peptide Concentrations*
PE (SE)
Demographics, n=510, model

R2=0.04,

Adjusted

Female gender
Older age at enrollment
Pre-Fontan Characteristics, n=466, model

R2=0.06,

Adjusted

Fontan Characteristics, n=510, model

Adjusted

0.21 (0.08)

0.01

0.05 (0.01)

<0.01

0.52 (0.16)

<0.01

R2=0.06**

Presence of systolic ventricular dysfunction on pre-Fontan echocardiography
R2=0.10,

p Value

R2=0.04**

R2=0.09,**

Type of Fontan connection

<0.01

Atriopulmonary

−0.38 (0.30)

Intracardiac lateral tunnel

−0.72 (0.28)

Extracardiac lateral tunnel

−1.01 (0.31)

Extracardiac conduit

−1.18 (0.30)

Other

reference

NIH-PA Author Manuscript

Post-Fontan Characteristics, n=510, model

R2=0.08,

Adjusted

R2=0.08**

Greater total number of complications
Post-Fontan thrombosis
Combined Medical History Characteristics, n=468, model

R2=0.16,

0.08 (0.03)

<0.01

0.45 (0.17)

<0.01

Adjusted

Presence of systolic ventricular dysfunction on pre-Fontan echocardiography

R2=0.15**

0.48 (0.15)

Type of Fontan connection

<0.01
<0.01

Atriopulmonary

−0.37 (0.32)

Intracardiac lateral tunnel

−0.58 (0.30)

Extracardiac lateral tunnel

−0.85 (0.33)

Extracardiac conduit

−1.07 (0.32)

Other

reference

Greater number of post-Fontan complications during follow-up

0.11 (0.03)

<0.01

Post-Fontan thrombosis during follow-up

0.41 (0.17)

0.02

Parent-Completed CHQ Summary Scores, n=483, model R2=0.05, Adjusted R2=0.04**
Lower Physical Functioning Summary score

0.01 (0.004)

0.02

NIH-PA Author Manuscript

Parent-Completed CHQ Domain Scores, n=503, model R2=0.06, Adjusted R2=0.06**
Lower Physical Functioning Domain score

0.007 (0.002)

Parent-Completed CHQ Health Conditions, n=494, model

R2=0.07,

Adjusted

Orthopedic / bone / joint problems
Allergy / sinus problems
Cardiopulmonary Exercise Testing, n=135, model

R2=0.17**,

Adjusted

Lower chronotropic index

<0.01

R2=0.06**

0.41 (0.13)

<0.01

0.26 (0.11)

0.02

R2=0.14*
1.56 (0.60)

0.01

Lower AW peak late diastolic velocity (m/sec)

1.40 (0.41)

<0.01

Longer duration of AV late diastohc inflow (msec)

0.01 (0.002)

<0.01

Echocardiography†, n=389, model R2=0.15, Adjusted R2=0.14***
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PE (SE)
Magnetic Resonance Imaging, n=153, model

NIH-PA Author Manuscript

Ventricular mass index >

95th

R2=0.33,

Adjusted

p Value

R2=0.31***

percentile

1.87 (0.28)

<0.01

*

after logarithmic transformation (with the natural base)

**

adjusted for age at enrollment and gender

***

adjusted for age at enrollment and gender, and type of Fontan connection

†

Missing echocardiographic variable values were imputed from the subset with mass-volume data

AVV, atrioventricular valve; CHQ, Child Health Questionnaire; PE, parameter estimate; SE, standard error
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